Mesenchymal stem cells (MSCs) are multipurpose cells found in bone marrow and fat tissue. They can differentiate into bone, cartilage, or fat, and produce anti-inflammatory molecules that may help repair damaged joints and tissues.
Mesenchymal stem cells have become the workhorse of regenerative medicine clinics across Europe. Unlike embryonic stem cells—which can become any cell type but raise ethical concerns—MSCs are adult-derived, abundant, and ethically uncontroversial. They live in bone marrow, fat tissue, and umbilical cord blood. A clinic can harvest bone marrow from your hip or liposuction fat from your abdomen, isolate the MSCs, expand them in culture for several weeks, and reintroduce them to the damaged site. The entire process respects your immune system because these are your own cells; rejection risk is minimal.
What makes MSCs special? Their multipotency. In the right chemical environment, an MSC can become an osteocyte (bone cell), chondrocyte (cartilage), or adipocyte (fat cell). This matters for joint and bone repair. Offer MSCs a scaffold in a knee joint and the chemical signals of cartilage damage, and many will differentiate into cartilage-producing chondrocytes. That's not magic—it's cellular programming responding to local environment—but it's what makes MSCs useful for osteoarthritis, where cartilage is worn away.
Beyond differentiation, MSCs secrete bioactive molecules: interleukins, growth factors, and anti-inflammatory cytokines. These substances diffuse through the damaged tissue, suppress inflammatory immune cells, and promote healing in nearby structures. A single injection of MSCs may produce clinical benefit not just through replacement of lost cells but through immunomodulation—toning down destructive inflammation. This paracrine effect, as it's called, sometimes persists for months after a single injection, making MSCs useful even in conditions where full cellular regeneration isn't realistic.
Two sourcing routes exist. Autologous MSCs are harvested from your own marrow or fat, cultured for 2–4 weeks, then reintroduced. Allogeneic MSCs come from a healthy donor, are cultured in bulk, and can be used off-the-shelf or after minimal customisation. Autologous treatments feel more personal and sidestep immunologic concerns entirely; allogeneic treatments are faster (treatment can begin within days) and cheaper if the clinic maintains a validated cell bank. Both are used for osteoarthritis; some conditions may benefit more from one route than the other.
What MSCs are not: they're not a cure. They don't reverse advanced arthritis in a single treatment. They don't work for everyone. Selection criteria matter—a patient with severe cartilage loss and bone-on-bone contact may not respond as well as someone with early-stage damage. Safety is generally strong; infection rates are low when proper GMP protocols are followed, and systemic toxicity is rare. But long-term data on very large populations is still accumulating. When a clinic offers MSCs, ask about their sourcing certification, cell viability testing results, and published follow-up outcomes for your specific condition.
Educational content; outcomes vary by patient and most uses are investigational — consult a physician. Reviewed by the StemCellAtlas editorial team.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita